Search
Search results
1502 results found
Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.
Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.
Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258.
Sullivan, KL, RA Hauser, and TA Zesiewicz. 2004. “Essential Tremor. Epidemiology, Diagnosis, and Treatment. Neurologist 2004;10:250-258.”. Neurologist.
Double-blinded, placebo-controlled study of entacapone in levodopa-treated patients with Parkinson disease. Archives of neurology, 61(10), 1563.
Olanow, CW, K Kieburtz, M Stern, R Watts, JW Langston, M Guarnieri, RA Hauser, and J Hubble. 2004. “Double-Blinded, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Parkinson Disease. Archives of Neurology, 61(10), 1563.”. Archives of Neurology.
Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003; 5:149-160.
Zesiewicz, TA, MJ Baker, M Wahba, and RA Hauser. 2003. “Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2003; 5:149-160.”. Curr Treat Options Neurol.
Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease.
Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.
Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
Hauser, RA, JP Hubble, and DD Truong. 2003. “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD. Neurology 2003;61:297-303.”. Neurology.
2025 HFpEF SUMMIT REGISTRATION OPEN
The HFpEF Summit is a bi-annual, two-day meeting which brings together internationally recognized leaders in the areas of clinical, translational and biological studies of heart failure with preserved ejection fraction (HFpEF). This summit is focused on the latest insights and innovations for...
Dr. Blair is a Co-Investigator of new $3.75 million NIH award to study links between COVID and Alzheimer's disease
Driving safety in Parkinson’s disease. Neurology 2002;59:1787-1788.
Zesiewicz, TA, CR Cimino, AR Malek, N Gardner, PL Leaverton, PB Dunne, and RA Hauser. 2002. “Driving Safety in Parkinson’s Disease. Neurology 2002;59:1787-1788.”. Neurology.